Impax Asset Management Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
– Sell
-2,587
Closed -$495K – 309
2023
Q4
$495K Sell
2,587
-316
-11% -$53.8K ﹤0.01% 340
2023
Q3
$514K Sell
2,903
-165
-5% -$31.5K ﹤0.01% 330
2023
Q2
$583K Buy
3,068
+48
+2% +$9.52K ﹤0.01% 327
2023
Q1
$605K Buy
3,020
+312
+12% +$65.6K ﹤0.01% 308
2022
Q4
$644K Sell
2,708
-954
-26% -$203K ﹤0.01% 298
2022
Q3
$733K Buy
3,662
+350
+11% +$66.8K ﹤0.01% 290
2022
Q2
$483K Sell
3,312
-786
-19% -$112K ﹤0.01% 325
2022
Q1
$669K Buy
4,098
+307
+8% +$46.8K ﹤0.01% 322
2021
Q4
$642K Sell
3,791
-12,521
-77% -$2.33M ﹤0.01% 332
2021
Q3
$3.08M Buy
16,312
+66
+0.4% +$12.4K 0.01% 220
2021
Q2
$2.75M Buy
16,246
+1
+0% +$146 0.01% 226
2021
Q1
$2.29M Buy
16,245
+110
+0.7% +$16.6K 0.01% 234
2020
Q4
$2.1M Sell
16,135
-35,031
-68% -$4.68M 0.01% 201
2020
Q3
$7.45M Buy
51,166
+21,074
+70% +$2.99M 0.07% 129
2020
Q2
$4.46M Buy
30,092
+8,754
+41% +$1.18M 0.05% 160
2020
Q1
$2.32M Buy
21,338
+18,879
+768% +$2.18M 0.03% 187
2019
Q4
$283K Buy
+2,459
New +$245K ﹤0.01% 263

Other funds holding ALNY

Impax Asset Management Group's ALNY Position: Q1 2024 in Review

Impax Asset Management Group sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2024, closing a stake of 2,587 shares — an estimated $495K sold.

Impax Asset Management Group first reported a position in ALNY in Q4 2019 and held it in 17 quarters. The position peaked at $7.45M in Q3 2020. 499 funds tracked by Wall St. Rank hold ALNY as of Q1 2024.

  • Impax Asset Management Group reported no remaining Alnylam Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Impax Asset Management Group sold 2,587 Alnylam Pharmaceuticals shares in Q1 2024, an estimated $495K.
  • Impax Asset Management Group first reported a position in Alnylam Pharmaceuticals in Q4 2019 and held it in 17 quarters.
  • Impax Asset Management Group's Alnylam Pharmaceuticals position peaked at $7.45M in Q3 2020.
  • 499 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2024.

Based on Impax Asset Management Group's 13F filing for Q1 2024, filed 30 Apr 2024.